REFERENCES
WHEN WORDS GET STUCK: THE COMPLEX CAUSES BEHIND STUTTERING
1. Robinson, J. (2022, August 23). I stutter. This is what you’re not hearing. The New York Times.
2. Choi, D., Conture, E., Walden, T., Jones, R., & Kim, H. (2016). Emotional diathesis, emotional stress, and childhood stuttering. Journal of Speech, Language, and Hearing Research, 59(4). doi: 10.1044/2015_JSLHR-S-14-0357
3. Edgren, B., Leanderson, R., & Levi, L. (1970). A research programme on stuttering and stress. Acta Oto-Laryngologica, 69(sup263), 113–118. doi: 10.3109/00016487009131533
4. Ajdacic-Gross, V., Bechtiger, L., Rodgers, S., Müller, M., Kawohl, W., von Känel, R., Mutsch, M., Rössler, W., Seifritz, E., Castelao, E., Strippoli, M.-P. F., Van deleur, C., Preisig, M., & Howell, P. (2018). Subtypes of stuttering determined by latent class analysis in two Swiss epidemiological surveys. PLOS ONE, 13(8). doi: 0.1371/journal.pone.0198450
5. Cohen, J. (2014). A new name for stuttering in DSM-5. American Psychological Association, 45(7), 51.
6. Yairi, E. (2007). Subtyping stuttering I: A review. Journal of Fluency Disorders, 32(3), 165–196. doi: 10.1016/j.jfludis.2007.04.001
7. Jiang, J., Lu, C., Peng, D., Zhu, C., & Howell, P. (2012). Classification of types of stuttering symp toms based on brain activity. PLOS ONE, 7(6), e39747. doi: 10.1371/journal.pone.0039747
8. Prasse, J. E., & Kikano, G. E. (2008). Stuttering: An Overview. American Family Physician, 77(9), 1271–1276. PMID: 18540491
9. Costa, D., & Kroll, R. (2000). Stuttering: An update for physicians. CMAJ: Canadian Medical Associa tion Journal, 162(13), 1849–1855. PMID: 10906923
10. Lawrence, M., & Barclay, D. M. (1998). Stuttering: A brief review. American Family Physician, 57(9), 2175–2178. PMID: 9606307
11. Reilly, S., Onslow, M., Packman, A., Cini, E., Con way, L., Ukoumunne, O. C., Bavin, E. L., Prior, M., Eadie, P., Block, S., & Wake, M. (2013). Natural History of Stuttering to 4 Years of Age: A Prospective Community-Based Study. Pediatrics, 132(3), 460–467. doi: 10.1542/peds.2012-3067
12. Almada, A., Simões, R., Constante, M., Casquinha,
P., & Heitor, M. J. (2016). Psychogenic stuttering: A case and review. European Psychiatry, 33(S1), S386–S387. doi: 10.1016/j.eurpsy.2016.01.1389
13. Van Borsel, J., & Taillieu, C. (2001). Neurogenic stuttering versus developmental stuttering: An observer judgment study. Journal of Communica tion Disorders, 34(5), 385–395. doi: 10.1016/S00219924(01)00057-0
14. Craig-McQuaide, A., Akram, H., Zrinzo, L., & Tripoli ti, E. (2014). A review of brain circuitries involved in stuttering. Frontiers in Human Neuroscience, 8. doi: 10.3389/fnhum.2014.00884
15. Sønsterud, H., Halvorsen, M. S., Feragen, K. B., Kir mess, M., & Ward, D. (2020). What works for whom? Multidimensional individualized stuttering thera py (MIST). Journal of Communication Disorders, 88, 106052. doi: 10.1016/j.jcomdis.2020.106052
16. Ludlow, C. L., Rosenberg, J., Salazar, A., Grafman, J., & Smutok, M. (1987). Site of penetrating brain lesions causing chronic acquired stuttering. An nals of Neurology, 22(1), 60–66. doi: 10.1002/ ana.410220114
17. Lundgren, K., Helm-Estabrooks, N., & Klein, R. (2010). Stuttering following acquired brain dam age: A review of the literature. Journal of Neuro linguistics, 23(5), 447–454. doi: 10.1016/j.jneurol ing.2009.08.008
18. Norman, R. S., Jaramillo, C. A., Eapen, B. C., Amuan, M. E., & Pugh, M. J. (2018). Acquired Stuttering in Veterans of the Wars in Iraq and Afghanistan: The Role of Traumatic Brain Injury, Post-Traumatic Stress Disorder, and Medications. Military Medi cine, 183(11–12), e526–e534. doi: 10.1093/milmed/ usy067
19. Grant, A. C., Biousse, V., Cook, A. A., & Newman, N. J. (1999). Stroke-Associated Stuttering. Archives of Neurology, 56(5), 624–627. doi: 10.1001/arch neur.56.5.624
20. Lebrun, Y., Leleux, Ch., & Retif, J. (1987). Neuro genic stuttering. Acta Neurochirurgica, 85, 103–109. doi: 10.1007/BF01456105
21. Chang, S. E., & Guenther, F. H. (2020). Involve ment of the Cortico-Basal Ganglia-Thalamocorti cal Loop in Developmental Stuttering. Frontiers in Psychology, 10. doi: 10.3389/fpsyg.2019.03088
22. Sherman, S. M., & Guillery, R. W. (2006). Exploring the thalamus and its role in cortical function, 2nd ed (pp. xxi, 484). MIT Press.
23. Bosch-Bouju, C., Hyland, B., & Parr-Brownlie, L. (2013). Motor thalamus integration of cortical, cerebellar and basal ganglia information: Impli cations for normal and parkinsonian conditions. Frontiers in Computational Neuroscience, 7. doi: 10.3389/fncom.2013.00163
49 GREY MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5 References
24. Alm, P. A. (2004). Stuttering and the basal gan glia circuits: A critical review of possible relations. Journal of Communication Disorders, 37(4), 325–369. doi: 10.1016/j.jcomdis.2004.03.001
25. Ingham, R. J., Ingham, J. C., Finn, P., & Fox, P. T. (2003). Towards a functional neural systems mod el of developmental stuttering. Journal of Fluen cy Disorders, 28(4), 297–318. doi: 10.1016/j.jflu dis.2003.07.004
26. Ludlow, C. L., & Loucks, T. (2003). Stuttering: A dynamic motor control disorder. Journal of Flu ency Disorders, 28(4), 273–295. doi: 10.1016/j.jflu dis.2003.07.001
27. Kraft, S. J., & Yairi, E. (2012). Genetic bases of stut tering: The state of the art, 2011. Folia Phoniatrica et Logopaedica, 64(1), doi: 10.1159/000331073
28. Bloodstein, O., & Ratner, N. B. (2008). A handbook on stuttering (6th ed). Thomson Delmar Learning.
29. Frigerio‐Domingues, C., & Drayna, D. (2017). Ge netic contributions to stuttering: The current ev idence. Molecular Genetics & Genomic Medicine, 5(2), 95–102. doi: 10.1002/mgg3.276
30. Kang, C., Riazuddin, S., Mundorff, J., Krasnewich, D., Friedman, P., Mullikin, J. C., & Drayna, D. (2010). Mutations in the lysosomal enzyme-targeting pathway and persistent stuttering. The New En gland Journal of Medicine, 362(8), 677–685. doi: 10.1056/NEJMoa0902630
31. Andy, O. J., & Bhatnagar, S. C. (1991). Thalamic-In duced Stuttering (Surgical Observations). Jour nal of Speech, Language, and Hearing Research, 34(4), 796–800. doi: 10.1044/jshr.3404.796
32. Felsenfeld, S., Kirk, K. M., Zhu, G., Statham, D. J., Neale, M. C., & Martin, N. G. (2000). A study of the genetic and environmental etiology of stutter ing in a selected twin sample. Behavior Genetics, 30(5), 359–366. doi: 10.1023/A:1002765620208
33. Hooper, T. (Director). (2010, November 26). The King’s Speech [Drama/History].
34. Alm, P. A. (2004a). Stuttering, emotions, and heart rate during anticipatory anxiety: A critical review. Journal of Fluency Disorders, 29(2), 123–133. doi: 10.1016/j.jfludis.2004.02.001
35. Góral - Półrola, J., Żychowska, M., Ziółkowski, A., & Pąchalska, M. (2015). Changes in gene expres sions associated with cell stress in the patient with chronic preservative stuttering. Acta Neuro psychologica, 13, 417–424.
36. Natke, U., Grosser, J., Sandrieser, P., & Kalveram, K. T. (2002). The duration component of the stress effect in stuttering. Journal of Fluency Disorders, 27(4), 305–318. doi: 10.1016/S0094730X(02)00163-8
37. Plexico, L., Manning, W. H., & DiLollo, A. (2005).
A phenomenological understanding of successful stuttering management. Journal of Fluency Disor ders, 30(1), 1–22. doi: 10.1016/j.jfludis.2004.12.001
38. Plexico, L., Manning, W. H., & Levitt, H. (2009). Coping responses by adults who stutter: Part II. Approaching the problem and achieving agency. Journal of Fluency Disorders, 34(2), 108–126. doi: 10.1016/j.jfludis.2009.06.003
39. Smith, A., & Weber, C. (2017). How stuttering de velops: The multifactorial dynamic pathways the ory. Journal of Speech, Language, and Hearing Research, 60(9), 2483–2505. doi: 10.1044/2017_ JSLHR-S-16-0343
A TRIP TO THE THERAPEUTIC WORLD OF PSYCHEDELIC MUSHROOMS
1. NBC Universal News Group. (2022, October 18). Participant on life-changing sobriety 7 years af ter psychedelics study: ‘there are no words’. NBC News.com.
2. Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., O’Donnell, K., Owens, L. T., Po drebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of heavy drinking days fol lowing psilocybin-assisted psychotherapy vs pla cebo in the treatment of adult patients with alco hol use disorder: A randomized clinical trial. JAMA Psychiatry, 79(10):953–962. doi: 10.1001/jamapsy chiatry.2022.2096
3. Guzmán, G., Allen, J. , & Gartz, J. (1998). A world wide geographical distribution of the neurotropic fungi, an analysis and discussion. Annali dei Mu seo civico, Rovereto, 14, 189–280
4. Akers, B. P., Ruiz, J. F., Piper, A. Ruck, C. A. P. (2011). A prehistoric mural in Spain depicting neurotropic Psilocybe Mushrooms? Economic Botany 65, 121–128. doi: 10.1007/s12231-011-9152-5
5. Winkelman, M. J. (2019). Introduction: Evidence for entheogen use in prehistory and world reli gions, Journal of Psychedelic Studies, 3(2), 43-62. doi: 10.1556/2054.2019.024
6. Samorini, G. (1992). The oldest representations of hallucinogenic mushrooms in the world (Sahara desert, 9000–7000 BP). Integration, 2(3), 69–78.
7. Bogoraz, V. (1909). The chukchee. social organi zation. The Jesup North Pacific Expedition 7, Social organization, 11, 537–733. New York: American Museum of Natural History.
8. Metzner, R. (1998). Hallucinogenic drugs and plants in psychotherapy and shamanism. Journal of psychoactive drugs, 30(4), 333–341. doi:10.1080 /02791072.1998.10399709
50 GREY MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5 References
9. Feeney, K. (2009). Revisiting Wasson’s Soma: Exploring the effects of preparation on the chemistry of amanita muscaria. Jour nal of Psychoactive Drugs 42(4), 499-506. doi: 10.1080/02791072.2010.10400712
10. Shah, N. C. (2015). Soma, an enigmatic, mysteri ous plant of the Vedic āryas: An appraisal. Indian Journal of History of Science, 50(1). doi: 10.16943/ ijhs/2015/v50i1/48110
11. Thomas, K., Malcolm, B., & Lastra, D. (2017). Psi locybin-assisted therapy: A review of a nov el treatment for psychiatric disorders. Jour nal of Psychoactive Drugs, 49(5), 446–455. doi: 10.1080/02791072.2017.1320734
12. Inserra, A. (2019). Current status of psyche delic therapy in Australia and New Zealand: Are we falling behind? Australian & New Zea land Journal of Psychiatry 53(3), 190-192. doi: 10.1177/0004867418824018
13. Strauss, N., Bright S. J., & Williams M. L. (2016). Australia should be initiating a psychedelic research program: What are the barriers? Australian & New Zealand Journal of Psychiatry 50(11):10361037. doi: 10.1177/0004867416670520
14. González-Mariscal, J. M. and Sosa-Cortés, P. E. (2022). Insights for modern applications of psi locybin therapy from a case study of tradition al mazatec medicine. Anthropol Conscious. doi: 10.1111/anoc.12168
15. Sahagún, Bernardino de. 1829. Historia general de las cosas de Nueva España. Tomo Segundo: Libros V - IX. México: Impr. del ciudadano A. Valdés.
16. Shepard, G. H. Jr. (2004). Central and South Amer ican shamanism. Shamanism: An Encyclopedia of World Beliefs, Practices, and Culture, 1, 365-370.
17. Kaishan, P. & Djoulakain, H. (2020). The science underground: Mycology as a queer discipline. Catalyst: Feminism, Theory, Technoscience, 6(2), 1-26. doi: 10.28968/cftt.v6i2.33523
18. Chi, T., & Gold, J. A. (2020). A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. Journal of the Neurological Sciences, 411, 116715. doi: 10.1016/j. jns.2020.116715
19. Wesson, D. R. (2011). Psychedelic drugs, hippie counterculture, speed and phenobarbital treat ment of sedative-hypnotic dependence: A jour ney to the Haight Ashbury in the sixties. Jour nal of Psychoactive Drugs, 43(2), 153–164. doi: 10.1080/02791072.2011.587708
20. Vitiello, M. (2021). The war on drugs: moral pan ic and excessive sentences. Cleveland State Law Review, 69(2), 441-484. doi: 10.2139/ssrn.3689183
21. Peipert, T. (2022, November 11). DMT, magic mush-
rooms decriminalization vote passed by Colora dans [Press release]. FOX31 Denver.
22. Green Horizons. (2020, June 10). Green Horizons research shows desire for psychedelics market is strong.
23. Principe, A. A. E. (2022). Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin. University of Guelph 14(3). doi:10.21083/surg.v14i1.6870
24. Rucker, J. J., Marwood, L., Ajantaival, R. L. J., Bird, C., Eriksson, H., Harrison, J., Lennard-Jones, M., Mistry, S., Saldarini, F., Stansfield, S., Tai, S. J., Williams, S., Weston, N., Malievskaia, E., & Young, A. H. (2022). The effects of psilocybin on cog nitive and emotional functions in healthy par ticipants: Results from a phase 1, randomized, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Jour nal of Psychopharmacology, 36(1), 114–125. doi: 10.1177/02698811211064720
25. Studerus, E., Kometer, M., Hasler, F., & Franz, X. V. (2011). Acute, subacute and long-term sub jective effects of psilocybin in healthy hu mans: A pooled analysis of experimental stud ies. J Psychopharmacol, 25(11), 1434-1452. doi: 10.1177/0269881110382466
26. Carhart-Harris, R., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A.,Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 21382143. doi: 10.1073/pnas.1119598109
27. Berger, M., Gray, J. A., & Roth, B. L. (2009). The expanded biology of serotonin. Annual Review of Medicine, 60(1), 355–366. doi: 10.1146/annurev. med.60.042307.110802
28. de Veen, B. T. H., Schellekens, A. F. A., Verhe ij, M. M. M., & Homberg, J. R. (2016). Psilocybin for treating substance use disorders? Expert Re view of Neurotherapeutics, 17(2), 203–212. doi: 10.1080/14737175.2016.1220834
29. Michael, P. B., Alyssa, A. F., Jessica, A. P., Claire, E. W., Barbosa, P., & Rick, J. S. (2015). Psilocybin-as sisted treatment for alcohol dependence: A proofof-concept study. J Psychopharmacol, 29(3), 289299. doi: 10.1177/0269881114565144
30. Johnson, M. W., Garcia-Romeu, A., Cosimano, M., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. doi: 10.1177/0269881114548296
31. Cahill, K., Stevens, S., & Lancaster, T. (2014).
51 GREY MATTERS
AT VASSAR
| ISSUE 5 References
JOURNAL
COLLEGE
Pharmacological treatments for smoking ces sation. JAMA. 311(2), 193–194. doi: 10.1001/ jama.2013.283787
32. Boulougouris, V., Glennon, J., & Robbins, T. (2007). Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial re versal learning in rats. Neuropsychopharmacol 33, 2007-2019. doi: 10.1038/sj.npp.1301584
33. Amodeo, D. A., Hassan, O., Klein, L., Halberstadt, A. L., & Powell S. B. (2020). Acute serotonin 2A receptor activation impairs behavioral flexibility in mice. Behavioral Brain Research. 395112861. doi: 10.1016/j.bbr.2020.112861
34. Furr, A., Lapiz-Bluhm M. D., & Morilak D. A. (2012) 5-HT2A receptors in the orbitofrontal cortex fa cilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. International Journal of Neu ropsychopharmacol. 15(9):1295–1305. doi: 10.1017/ S1461145711001441
35. Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2021) The selective 5-HT2A receptor agonist 25CN-NBOH does not affect reversal learning in mice. Behavioral Pharmacology. 32(5), 448–452. doi: 10.1097/FBP.0000000000000626
36. Asan, E., Steinke, M. & Lesch, K. P. (2013). Sero tonergic innervation of the amygdala: Targets, receptors, and implications for stress and anxi ety. Histochem Cell Biol 139, 785–813. doi:10.1007/ s00418-013-1081-1
37. Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015). Psilocybin-induced decrease in amyg dala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry, 78(8), 572-581. doi:10.1016/j.biopsych.2014.04.010
38. Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020). The experimental ef fects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research, 284. doi: 10.1016/j.psychres.2020.112749
39. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assist ed therapy on major depressive disorder. JAMA Psychiatry, 78(5), 481. doi: 10.1001/jamapsychia try.2020.3285
40. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psi locybin produces substantial and sustained de creases in depression and anxiety in patients with life-threatening cancer: A randomized dou ble-blind trial. Journal of psychopharmacology,
30(12), 1181–1197. doi: 10.1177/0269881116675513
41. Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: Fmri-measured brain mechanisms. Scientific Reports, 7(1). doi: 10.1038/s41598-017-13282-7
42. Raichle, M. E. (2015). The brain’s default mode net work. Annual Review of Neuroscience, 38(1), 433–447. doi: 10.1146/annurev-neuro-071013-014030
43. Krukow, P., Jonak, K., Grochowski, C., Plechawska-Wójcik, M., & Karakuła-Juchnowicz, H. (2020). Resting-state hyperconnectivity with in the default mode network impedes the ability to initiate cognitive performance in first-episode schizophrenia patients. Progress in Neuro-Psy chopharmacology and Biological Psychiatry, 102, 109959. doi: 10.1016/j.pnpbp.2020.109959
44. Smigielski, L., Scheidegger, M., Kometer, M., & Vol lenweider, F. X. (2019). Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. NeuroImage, 196, 207–215. doi: 10.1016/j.neuroimage.2019.04.009
45. Doblin, R. E., Christiansen, M., Jerome, L., & Burge, B. (2019). The past and future of psy chedelic science: An introduction to this issue. Journal of Psychoactive Drugs, 51(2), 93–97. doi: 10.1080/02791072.2019.1606472
46. Lutkajtis, A. (2021). Four individuals’ experiences during and following a psilocybin truffle retreat in the Netherlands. Journal of Psychedelic Studies, 5(1), 22–32. doi: 10.1556/2054.2021.00162
47. Andrade, C. (2020). Sample size and its impor tance in research. Indian Journal of Psycholog ical Medicine, 42(1), 102–103. doi:10.4103/ijpsym. ijpsym_504_19
48. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBat tista, C., Dunlop, B. W., Eisen, K., Feifel, D., … Ma lievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. doi: 10.1056/nejmoa2206443
NATURE’S SCAFFOLDING: THE EXTRACELLULAR MATRIX
1. Frantz, C., Stewart, K. M., & Weaver, V. M. (2010). The extracellular matrix at a glance. Journal of Cell Science, 123(Pt 24), 4195–4200. doi: 10.1242/
52 GREY MATTERS JOURNAL
|
References
AT VASSAR COLLEGE
ISSUE 5
jcs.023820
2. Yue B. (2014). Biology of the extracellular matrix: an overview. Journal of Glaucoma, 23(8 Suppl 1), S20–S23. doi: 10.1097/IJG.0000000000000108
3. Frischknecht, R., & Gundelfinger, E. D. (2012). The brain’s extracellular matrix and its role in synap tic plasticity. Advances in Experimental Medicine and Biology, 970, 153–171. doi: 10.1007/978-3-70910932-8_7
4. Silver, D. J., & Silver, J. (2014). Contributions of chondroitin sulfate proteoglycans to neurode velopment, injury, and cancer. Current opin ion in neurobiology, 27, 171–178. doi: 10.1016/j. conb.2014.03.016
5. Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S., & Yong, V. W. (2013). Pathophysiology of the brain extracellular matrix: a new target for remy elination. Nature Reviews. Neuroscience, 14(10), 722–729. doi: 10.1038/nrn3550
6. Xu, L., Nirwane, A., & Yao, Y. (2018). Basement membrane and blood-brain barrier. Stroke and Vascular Neurology, 4(2), 78–82. doi: 10.1136/svn2018-000198
7. Carulli, D., & Verhaagen, J. (2021). An extracellular perspective on CNS maturation: Perineuronal nets and the control of plasticity. International Journal of Molecular Sciences, 22(5), 2434. doi: 10.3390/ ijms22052434
8. Cheng, Q., Silvano, E., & Bedny, M. (2020). Sensi tive periods in cortical specialization for language: insights from studies with Deaf and blind individ uals. Current opinion in behavioral sciences, 36, 169–176. doi: 10.1016/j.cobeha.2020.10.011
9. Power, J. D., & Schlaggar, B. L. (2017). Neural plas ticity across the lifespan. Wiley Interdisciplinary Reviews. Developmental Biology, 6(1), 10.1002/ wdev.216. doi: 10.1002/wdev.216
10. Mirzadeh, Z., Alonge, K. M., Cabrales, E., Her ranz-Pérez, V., Scarlett, J. M., Brown, J. M., Has souna, R., Matsen, M. E., Nguyen, H. T., Garcia-Ver dugo, J. M., Zeltser, L. M., & Schwartz, M. W. (2019). Perineuronal Net Formation during the Critical Period for Neuronal Maturation in the Hypotha lamic Arcuate Nucleus. Nature metabolism, 1(2), 212–221. doi: 10.1038/s42255-018-0029-0
11. Sigal, Y. M., Bae, H., Bogart, L. J., Hensch, T. K., & Zhuang, X. (2019). Structural maturation of cortical perineuronal nets and their perforating synapses revealed by superresolution imaging. Proceedings of the National Academy of Sciences of the United States of America, 116(14), 7071–7076. doi: 10.1073/ pnas.1817222116
12. Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018). The perineuronal ‘safety’ net? Perineu-
ronal net abnormalities in neurological disorders. Frontiers in Molecular Neuroscience, 11, 270. doi: 10.3389/fnmol.2018.00270
13. Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current concepts and treatments of schizophre nia. Molecules (Basel, Switzerland), 23(8), 2087. doi: 10.3390/molecules23082087
14. Pantazopoulos, H., & Berretta, S. (2016). In sick ness and in health: Perineuronal nets and synap tic plasticity in psychiatric disorders. Neural Plas ticity, 9847696. doi: 10.1155/2016/9847696
15. Gaudet, A. D., &Fonken, L. K. (2018) Glial Cells Shape Pathology and Repair After Spinal Cord In jury. Neurotherapeutics: the journal of the Amer ican Society for Experimental NeuroTherapeutics, 15(3), 554-577. doi: 10.1007/s13311-018-0630-7
16. Allen, N. J., & Lyons, D. A. Glia as architects of central nervous system formation and function. Science (New York, N.Y.), 362(6411), 181-185. doi: 10.1126/science.aat0473
17. Sun, Y., Xu, S., Jiang, M., Liu, X., Yang, L., Bai, Z., & Yang., Q. Role of the extracellular matrix in Alzhei mer’s disease. Frontiers in aging neuroscience, 13, 707466. doi: 10.3389/fnagi.2021.707466
18. George, N., & Geller, H. M. (2018). Extracellular matrix and traumatic brain injury. Journal of Neu roscience Research, 96(4), 573–588. doi: 10.1002/ jnr.24151
19. Cornez, G., Collignon, C., Müller, W., Cornil, C. A., Ball, G. F., & Balthazart, J. (2020). Development of perineuronal nets during ontogeny correlates with sensorimotor vocal learning in canaries. eNeuro, 7(2). doi: 10.1523/ENEURO.0361-19.2020
20. Covey, M. V, Jiang, Y., Alli, V. V., Yang, Z., Levison, S. W., (2010) Defining the critical period for neo cortical neurogenesis after pediatric brain in jury. Developmental neuroscience, 32, 5-6. doi: 10.1159/000321607
21. Nudo, R. J., (2013). Recovery after brain inju ry: mechanisms and principles. Frontiers in human neuroscience, 7(887). doi: 10.3389/fn hum.2013.00887
22. Yang, T., Dai, Y., Chen, G., Cui, S., (2020). Dissect ing the dual role of the glial scar and scar-form ing astrocytes in spinal cord injury. Frontiers in cellular neuroscience, 14(78). doi: 10.3389/fn cel.2020.00078
23. Soleman, S., Filippov, M. A., Dityatev, A., & Fawcett, J. W. (2013). Targeting the neural extracellular ma trix in neurological disorders. Neuroscience, 253, 194–213. doi: 10.1016/j.neuroscience.2013.08.050
24. Basuodan, R., Basu, A. P., & Clowry, G. J. (2018). Human neural stem cells dispersed in artificial ECM form cerebral organoids when grafted in vivo.
53 GREY MATTERS
AT VASSAR COLLEGE | ISSUE 5 References
JOURNAL
Journal of Anatomy, 233(2), 155–166. doi: 10.1111/ joa.12827
25. Jiang, Y., Li, R., Han, C., & Huang, L. (2021). Ex tracellular matrix grafts: From preparation to ap plication (Review). International Journal of Mo lecular Medicine, 47(2), 463–474. doi: 10.3892/ ijmm.2020.4818
26. Wang, S., Zhu, C., Zhang, B., Hu, J., Xu, J., Xue, C., Bao, S., Gu, X., Ding, F., Yang, Y., Gu, X., & Gu, Y. (2022). BMSC-derived extracellular matrix bet ter optimizes the microenvironment to support nerve regeneration. Biomaterials, 280, 121251. doi: 10.1016/j.biomaterials.2021.121251
27. Maguire G. (2018). Neurodegenerative diseases are a function of matrix breakdown: how to rebuild extracellular matrix and intracellular matrix. Neu ral Regeneration Research, 13(7), 1185–1186. doi: 10.4103/1673-5374.235026
28. Vo, A. N., Kundu, S., Strong, C., Jung, O., Lee, E., Song, M. J., Boutin, M. E., Raghunath, M., & Ferrer, M. (2022). Enhancement of neuroglial extracellular matrix formation and physiological activity of dopaminergic neural cocultures by macromo lecular crowding. Cells, 11(14), 2131. doi: 10.3390/ cells11142131
29. Wu, Y., Wang, J., Shi, Y., Pu, H., Leak, R. K., Liou, A., Badylak, S. F., Liu, Z., Zhang, J., Chen, J., & Chen, L. (2017). Implantation of brain-derived extracel lular matrix enhances neurological recovery after traumatic brain injury. Cell Transplantation, 26(7), 1224–1234. doi: 10.1177/0963689717714090
30. Zhao, R. R., & Fawcett, J. W. (2013). Combination treatment with chondroitinase ABC in spinal cord injury--breaking the barrier. Neuroscience Bulle tin, 29(4), 477–483. doi: 10.1007/s12264-013-13592
31. Sharma, K., Selzer, M. E., & Li, S. (2012). Scar-me diated inhibition and CSPG receptors in the CNS. Experimental Neurology, 237(2), 370–378. doi: 10.1016/j.expneurol.2012.07.009
32. Tran, A. P., Warren, P. M., Silver, J.,(2022). New in sights into glial scar formation after spinal cord injury. Cell and tissue research, 387(3), 319-336. doi: 10.1007/s00441-021-03477-w
33. Sánchez-Ventura, J., Lane, M. A., Udina, E., (2022). The role and modulation of spinal perineuronal nets in the healthy and injured spinal cord. Fron tiers in cellular neuroscience, 16, 893857. doi: 10.3389/fncel.2022.893857
A LITTLE-KNOWN SIDE EFFECT OF CHEMOTHERAPY: CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 can cers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. doi: 10.3322/caac.21660
2. Shields, M. (2017). Chemotherapeutics. Pharma cognosy, 295–313. doi: 10.1016/b978-0-12-8021040.00014-7
3. Schirrmacher, V. (2019). From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treat ment (review). International journal of oncology. doi: 10.3892/ijo.2018.4661
4. Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Sal gado, J., & Ruiz-Frutos, C. (2020). Relationship between chemotherapy-induced adverse reac tions and health-related quality of life in patients with breast cancer. Medicine, 99(33). doi: 10.1097/ md.0000000000021695
5. Tofthagen, C., Overcash, J., & Kip, K. (2011). Falls in persons with chemotherapy-induced peripher al neuropathy. Supportive Care in Cancer, 20(3), 583–589. doi: 10.1007/s00520-011-1127-7
6. Arunachalam, S. S., Shetty, A. P., Panniyadi, N., Meena, C., Kumari, J., Rani, B., Das, P., & Kumari, S. (2021). Study on knowledge of Chemothera py’s adverse effects and their self-care ability to manage - the cancer survivors impact. Clinical Epidemiology and Global Health, 11, 100765. doi: 10.1016/j.cegh.2021.100765
7. Tanay, M. A., Robert, G., Rafferty, A. M., Moss‐Mor ris, R., & Armes, J. (2021). Clinician and patient experiences when providing and receiving infor mation and support for managing chemothera py-induced peripheral neuropathy: A qualitative multiple methods study. European Journal of Cancer Care, 31(1). doi: 10.1111/ecc.13517
8. Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014). Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropa thy: A systematic review and meta-analysis. Pain, 155(12), 2461–2470. doi: 10.1016/j.pain.2014.09.020
9. Vilholm, O. J., Christensen, A. A., Zedan, A. H., & Itani, M. (2014). Drug-induced peripheral neurop athy. Basic & Clinical Pharmacology & Toxicology, 115(2), 185–192. doi: 10.1111/bcpt.12261
10. Jones, M. R., Urits, I., Wolf, J., Corrigan, D., Col
54 GREY
MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5 References
burn, L., Peterson, E., Williamson, A., & Viswanath, O. (2020). Drug-induced peripheral neuropathy: A narrative review. Current Clinical Pharmacology, 15(1), 38–48. doi: 10.2174/157488471466619012115 4813
11. Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017). Chemotherapy-induced peripheral neu ropathy: A current review. Annals of Neurology, 81(6), 772–781. doi: 10.1002/ana.24951
12. Maihöfner, C., Diel, I., Tesch, H., Quandel, T., & Bar on, R. (2021). Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsa icin. Supportive Care in Cancer, 29(8), 4223–4238. doi: 10.1007/s00520-021-06042-x
13. Chan, C. W., Cheng, H., Au, S. K., Leung, K. T., Li, Y. C., Wong, K. H., & Molassiotis, A. (2018). Liv ing with chemotherapy-induced peripheral neu ropathy: Uncovering the symptom experience and self-management of neuropathic symp toms among cancer survivors. European Journal of Oncology Nursing, 36, 135–141. doi: 10.1016/j. ejon.2018.09.003
14. Kerckhove, N., Collin, A., Condé, S., Chaleteix, C., Pezet, D., & Balayssac, D. (2017). Long-term ef fects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripher al neuropathies: A comprehensive literature re view. Frontiers in Pharmacology, 8. doi: 10.3389/ fphar.2017.00086
15. Brzeziński, K. (2012). Chemotherapy-induced polyneuropathy. part I. Pathophysiology [Polish version: Polineuropatia Wywołana chemioterapią. Część I. Patofizjologia p. 79]. Współczesna Onko logia, 1, 72–85. doi: 10.5114/wo.2012.27341
16. Omran, M., Belcher, E. K., Mohile, N. A., Kesler, S. R., Janelsins, M. C., Hohmann, A. G., & Kleckner, I. R. (2021). Review of the role of the brain in che motherapy-induced peripheral neuropathy. Fron tiers in Molecular Biosciences, 8. doi: 10.3389/ fmolb.2021.693133
17. Speck, R. M., Sammel, M. D., Farrar, J. T., Hen nessy, S., Mao, J. J., Stineman, M. G., & DeMichele, A. (2012). Abstract P4-13-01: Racial disparities in the incidence of dose-limiting chemotherapy in duced peripheral neuropathy. Cancer Research, 72(24_Supplement). doi: 10.1158/0008-5472. sabcs12-p4-13-01
18. Colvin, L. A. (2019). Chemotherapy-induced pe ripheral neuropathy: Where are we now? Pain, 160(1). doi: 10.1097/j.pain.0000000000001540
19. Daneman, R., & Prat, A. (2015). The blood–brain barrier. Cold Spring Harbor Perspectives in Biolo gy, 7(1). doi: 10.1101/cshperspect.a020412
20. Grisold, W., Cavaletti, G., & Windebank, A. J. (2012). Peripheral neuropathies from Chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology, 14(suppl 4), iv45–iv54. doi: 10.1093/neuonc/nos203
21. Shim, H. S., Bae, C., Wang, J., Lee, K.-H., Hankerd, K. M., Kim, H. K., Chung, J. M., & La, J.-H. (2019). Pe ripheral and central oxidative stress in chemother apy-induced neuropathic pain. Molecular Pain, 15, 174480691984009. doi: 10.1177/1744806919840098
22. Duggett, N. A., Griffiths, L. A., McKenna, O. E., de Santis, V., Yongsanguanchai, N., Mokori, E. B., & Flatters, S. J. L. (2016). Oxidative stress in the de velopment, maintenance and resolution of pacl itaxel-induced painful neuropathy. Neuroscience, 333, 13–26. doi: 10.1016/j.neuroscience.2016.06.050
23. Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Man nino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bit to, A. (2017). Oxidative stress: Harms and benefits for human health. Oxidative Medicine and Cellular Longevity, 2017, 1–13. doi: 10.1155/2017/8416763
24. Areti, A., Ganesh Yerra, V., Komirishetty, P., & Ku mar, A. (2016). Potential therapeutic benefits of maintaining mitochondrial health in peripheral neuropathies. Current Neuropharmacology, 14(6), 593–609. doi: 10.2174/1570159x14666151126215358
25. Campbell, J. N., & Meyer, R. A. (2006). Mechanisms of neuropathic pain. Neuron, 52(1), 77–92. doi: 10.1016/j.neuron.2006.09.021
26. Kanat, O., Ertas, H., & Caner, B. (2017). Plati num-induced neurotoxicity: A review of possible mechanisms. World Journal of Clinical Oncology, 8(4), 329. doi: 10.5306/wjco.v8.i4.329
27. Banach, M., Juranek, J. K., & Zygulska, A. L. (2016). Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain and Behavior, 7(1). doi: 10.1002/brb3.558
28. Saif, M. W., & Reardon, J. (2005). Management of oxaliplatin-induced peripheral neuropathy. Ther apeutics and clinical risk management, 1(4), 249–258. PMID: 18360567
29. Yang, Y., Zhao, B., Gao, X., Sun, J., Ye, J., Li, J., & Cao, P. (2021). Targeting strategies for Oxaliplatin-in duced peripheral neuropathy: Clinical syndrome, molecular basis, and drug development. Journal of Experimental & Clinical Cancer Research, 40(1). doi: 10.1186/s13046-021-02141-z
30. Zheng, H., Xiao, W. H., & Bennett, G. J. (2011). Func tional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Experimental Neurology, 232(2), 154–161. doi: 10.1016/j.expneu rol.2011.08.016
31. Ibrahim, E. Y., & Ehrlich, B. E. (2020). Prevention
55 GREY
References
MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5
of chemotherapy-induced peripheral neuropathy: A review of recent findings. Critical Reviews in Oncology/Hematology, 145, 102831. doi: 10.1016/j. critrevonc.2019.102831
32. Toyama, S., Shimoyama, N., Ishida, Y., Koyasu, T., Szeto, H. H., & Shimoyama, M. (2014). Characteri zation of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies. Anesthesiology, 120(2), 459–473. doi: 10.1097/01.anes.0000435634.34709.65
33. Liu, Z., Ren, Z., Zhang, J., Chuang, C.-C., Kan daswamy, E., Zhou, T., & Zuo, L. (2018). Role of Ros and nutritional antioxidants in human dis eases. Frontiers in Physiology, 9. doi: 10.3389/ fphys.2018.00477
34. Di Cesare Mannelli, L., Zanardelli, M., Failli, P., & Ghelardini, C. (2012). Oxaliplatin-induced neurop athy: Oxidative stress as pathological mechanism. Protective effect of Silibinin. The Journal of Pain, 13(3), 276–284. doi: 10.1016/j.jpain.2011.11.009
35. Cruccu, G., Sommer, C., Anand, P., Attal, N., Baron, R., Garcia-Larrea, L., Haanpaa, M., Jensen, T. S., Serra, J., & Treede, R.-D. (2010). EFNS guidelines on Neuropathic pain assessment: Revised 2009. European Journal of Neurology, 17(8), 1010–1018. doi: 10.1111/j.1468-1331.2010.02969.x
36. Park, S. B., Alberti, P., Kolb, N. A., Gewandter, J. S., Schenone, A., & Argyriou, A. A. (2019). Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotox icity. Journal of the Peripheral Nervous System, 24(S2). doi: 10.1111/jns.12333
37. Zhi, W. I., Baser, R. E., Kwon, A., Chen, C., Li, S. Q., Piulson, L., Seluzicki, C., Panageas, K. S., Harte, S. E., Mao, J. J., & Bao, T. (2021). Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantita tive sensory testing. Breast Cancer Research and Treatment, 186(3), 761–768. doi: 10.1007/s10549020-06079-2
38. Ferrier, J., Pereira, V., Busserolles, J., Authier, N., & Balayssac, D. (2013). Emerging trends in un derstanding chemotherapy-induced peripheral neuropathy. Current Pain and Headache Reports, 17(10). doi: 10.1007/s11916-013-0364-5
39. Bao, T., Basal, C., Seluzicki, C., Li, S. Q., Seidman, A. D., & Mao, J. J. (2016). Long-term chemothera py-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk. Breast Cancer Research and Treatment, 159(2), 327–333. doi: 10.1007/s10549-016-3939-0
40. Cavaletti, G., & Marmiroli, P. (2020). Management of Oxaliplatin-induced peripheral sensory neu-
ropathy. Cancers, 12(6), 1370. doi: 10.3390/can cers12061370
41. Hershman, D. L., Lacchetti, C., & Loprinzi, C. L. (2014). Prevention and management of chemo therapy-induced peripheral neuropathy in survi vors of adult cancers: American Society of Clini cal Oncology Clinical Practice Guideline summary. Journal of Oncology Practice, 10(6). doi: 10.1200/ jop.2014.001776
RUNNING UP THAT HILL: THE STRANGER THINGS ABOUT LISTENING TO MUSIC
1. Zhang, S. (2020). The positive influence of music on the human brain. Journal of Behavioral and Brain Science, 10(01), 95–104. doi: 10.4236/ jbbs.2020.101005
2. Raglio, A. (2015). Effects of music and music ther apy on mood in neurological patients. World Jour nal of Psychiatry, 5(1), 68. doi: 10.5498/wjp.v5.i1.68
3. White, H. J., Helwany, M., Peterson, D. C. (2022). Anatomy, head and neck, ear organ of corti. Stat Pearls Publishing. PMID: 30855919
4. Tsukano, H. (2017). Corrigendum: Reconsidering tonotopic maps in the auditory cortex and lem niscal auditory thalamus in mice. Frontiers in Neural Circuits, 11. doi: 10.3389/fncir.2017.00039
5. Peterson, D. C., Reddy, V., Hamel, R. N. (2021) Neu roanatomy, auditory pathway. StatPearls Publish ing. PMID: 30335344
6. Humphries, C., Liebenthal, E., & Binder, J. R. (2010). Tonotopic organization of the human au ditory cortex. NeuroImage, 50(3), 1202–1211. doi: 10.1016/j.neuroimage.2010.01.046
7. Warren, J. (2008). How does the brain process music? Clinical Medicine, 8(1), 32–36. doi: 10.7861/ clinmedicine.8-1-32
8. Jäncke, L. (2008). Music, memory and emotion. Journal of Biology, 7(6), 21. doi: 10.1186/jbiol82
9. Koelsch, S. (2018). Investigating the neural encod ing of emotion with music. Neuron, 98(6), 1075–1079. doi: 10.1016/j.neuron.2018.04.029
10. Schaefer, H. E. (2017). Music-evoked emotions— current studies. Frontiers in Neuroscience, 11. doi:10.3389/fnins.2017.00600
11. Koelsch, S. (2009). A neuroscientific perspective on music therapy. Annals of the New York Academy of Sciences, 1169(1), 374–384. doi: 10.1111/j.17496632.2009.04592.x
12. Karim, H. T., Tudorascu, D. L., Butters, M. A., Walk er, S., Aizenstein, H. J., & Andreescu, C. (2017). In the grip of worry: Cerebral blood flow changes during worry induction and reappraisal in late-life
56 GREY MATTERS JOURNAL AT
| ISSUE 5 References
VASSAR COLLEGE
generalized anxiety disorder. Translational Psychi atry, 7(9). doi: 10.1038/tp.2017.215
13. Salgado, S., & Kaplitt, M. G. (2015). The nucleus accumbens: A comprehensive review. Stereotac tic and Functional Neurosurgery, 93(2), 75–93. doi: 10.1159/000368279
14. Salimpoor, V. N., Benovoy, M., Larcher, K., Dagh er, A., & Zatorre, R. J. (2011). Anatomically distinct dopamine release during anticipation and experi ence of peak emotion to music. Nature Neurosci ence, 14(2), 257–262. doi: 10.1038/nn.2726
15. Trimble, M., & Hesdorffer, D. (2017). Music and the brain: The neuroscience of music and musical ap preciation. BJPsych. International, 14(2), 28–31. doi: 10.1192/s2056474000001720
16. Jia, H., Guerin, R. J., Barile, J. P., Okun, A. H., McK night-Eily, L., Blumberg, S. J., Njai, R., & Thomp son, W. W. (2021). National and state trends in anxiety and depression severity scores among adults during the COVID-19 pandemic — United States, 2020–2021. MMWR. Morbidity and Mortality Weekly Report, 70(40), 1427–1432. doi: 10.15585/ mmwr.mm7040e3
17. Maratos A. S., Gold C., Wang X., Crawford M. J. Music therapy for depression. Cochrane Data base Syst Rev. 2008 Jan 23;(1):CD004517. doi: 10.1002/14651858.CD004517.pub2
18. Kalin, N. H. (2020). Novel insights into pathological anxiety and anxiety-related disorders. American Journal of Psychiatry, 177(3), 187–189. doi: 10.1176/ appi.ajp.2020.20010057
LOST IN MIGRATION: EXPLORING THE ROOTS OF GREY MATTER HETEROTOPIA
1. Zając-Mnich, M., Kostkiewicz, A., Wiesław, G., Dziurzyńska-Białek, E., Solińska, A., Stopa, J., & Kucharska-Miąsik, I. (2014). Clinical and morpho logical aspects of gray matter heterotopia type developmental malformations. Polish Journal of Radiology, 79, 502–507. doi:10.12659/PJR.890549
2. Bear, M. F., Connors, B.W., & Paradiso, M.A. (2015). Neuroscience: Exploring the brain (4th ed.). Wolt ers Kluwer Health
3. Mercadante, A. A., & Tadi, P. (2022). Neuroanat omy, Gray Matter. StatPearls Publishing. PMID: 31990494
4. Rahimi-Balaei, M., Bergen, H., Kong, J., & Marzban, H. (2018). Neuronal migration during development of the cerebellum. Frontiers in cellular neurosci ence, 12, 484. doi:10.3389/fncel.2018.00484
5. Meechan, D. W., Maynard, T. M., Tucker, E. S., & La Manita, A. S. (2010). Three phases of DiGeorge/22q11
deletion syndrome pathogenesis during brain de velopment: Patterning, proliferation, and mito chondrial functions of 22q11 genes. International Journal of Developmental Neuroscience, 29(3), 283–294. doi:10.1016/j.ijdevneu.2010.08.005
6. Serevino, M., Geraldo, A. F., Utz, N., Tortora, D., Pogledic, I., Klonowski, W., Triulzi, F., Arrigoni, F., Mankad, K., Leventer, R. J., Mancini, G. M. S., Bar kovich, J.A., & Lequin, M. H. (2020). Definitions and classification of malformations of cortical development: Practical guidelines. Brain, 143(10), 2874–2894. doi:10.1093/brain/awaa174
7. Vasung, L., Rezayev, A., Yun, H.J., Song, J. W., van der Kouwe, A., Stewart, N., Palani, A., Shiohana, T., Chouinard-Decorte, F., Levman, J., & Takahashi, E. (2019). Structural and diffusion MRI analyses with histological observations in patients with lissen cephaly. Frontiers in Cellular Developmental Biol ogy, 7, 124. doi:10.3389/fcell.2019.00124
8. Zinkstok, J. R., Boot, E., Bassett, A. S., Hiroi, N., Butcher, N. J., Vingerhoets, C., Vorstman, J. A. S., & van Amelsvoort, T. A. M. J. (2019). Neurobiological perspective of 22q11.2 deletion syndrome. Lan cet Psychiatry, 6(11), 951–960. doi:10.1016/S22150366(19)30076-8
9. Thompson, C. A., Karelis, J., Middleton, F. A., Gen tile, K., Coman, I. L., Radoeva, P. D., Mehta, R., Fre mont, W. P., Antshel, K. M., Faraone, S. V., & Kates, W. R. (2017). Associations between neurodevelop mental genes, neuroanatomy, and ultra high risk symptoms of psychosis in 22q11.2 deletion syn drome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 174(3), 295–314. doi:10.1002/ajmg.b.32515
10. Drobinin, V., van Gestel, H., Zwicker, A., MacKenzie, L., Cumby, J., Patterson, V. C., Vallis, E. H. Camp bell, N., Hajek, T., Helmick, C. A., Schmidt, M. H, Alda, M., Bowen, C. V., & Uher, R. (2020). Psychot ic symptoms are associated with lower cortical folding in youth at risk for mental illness. Journal of Psychiatry and Neuroscience, 45(2), 125–133. doi:10.1503/jpn.180144
11. Dufour, F., Schaer, M., Debanné, M., Farhoumand, R., Glaser, B., & Eliez, S. (2008). Cingulate gyral reductions are related to low executive function ing and psychotic symptoms in 22q11.2 deletion syndrome. Neuropsychologia, 46(12), 2986–2992. doi:10.1016/j.neuropsychologia.2008.06.012
12. Kiehl, T. R., Chow, E. W. C., Mikulis, D. J., George, S. R., & Bassett, A. S. (2009). Neuropathologic fea tures in adults with 22q11.2 deletion syndrome. Cerebral Cortex, 19(1), 153–164. doi:10.1093/cercor/ bhn066
13. Lippi, G. (2017). Neuropsychiatric symptoms and
ISSUE 5
57 GREY
References
MATTERS JOURNAL AT VASSAR COLLEGE |
diagnosis of grey matter heterotopia: A casebased reflection. South African Journal of Psychi atry, 23, 923. doi:10.4102/sajpsychiatry.v23i0.923
14. The American Psychiatric Association. (2022). Di agnostic and statistical manual of mental dis orders (5th ed., text revision). American Psychi atric Association Publishing. doi:10.1176/appi. books.9780890425787
15. Picchioni, M. M., & Murray, R. M. (2007). Schizophre nia. British Medical Journal, 335(91). doi:10.1136/ bmj.39227.616447.BE
16. Rahman, T., & Lauriello, J. (2016). Schizophrenia: An overview. Focus, 14(3), 300–307. doi:10.1176/ appi.focus.20160006
17. Howes, O. D., McCutcheon, R., Owen, M. J., & Mur ray, R. M. (2017). The role of genes, stress, and dopamine in the development of schizophrenia. Biological Psychiatry, 81(1), 9–20. doi:10.1016/j.bio psych.2016.07.014
18. Ramanathan, S., Mattiaccio, L. M., Coman, I. L., Botti, J. C., Fremont, W., Faraone, S. V., & Antshel, K. M., Kates, W. R. (2017). Longitudinal trajectories of cortical thickness as a biomarker for psycho sis in individuals with 22q11.2 deletion syndrome. Schizophrenia Research, 188, 35–41. doi:10.1016/j. schres.2016.11.041
19. Schaer, M., Debanné, M., Cuadra, M. B., Ottet, M., Glaser, B., Thiran, J., & Eliez, S. (2009). Deviant trajectories of cortical maturation in 22q11.2 de letion syndrome (22q11DS): A cross-sectional and longitudinal study. Schizophrenia Research, 115(23), 182–190. doi:10.1016/j.schres.2009.09.016
20. Karayiorgou, M., Simon, T. J., & Gogos, J. A. (2010). 2q11.2 microdeletions: Linking DNA structural variation to brain dysfunction and schizophre nia. Natural Reviews Neuroscience, 11(6), 402–416. doi:10.1038/nrn2841
21. The International Schizophrenia Consortium (2008). Rare chromosomal deletions and duplica tions increase risk of schizophrenia. Nature, 455, 237–241. doi:10.1038/nature07239
22. Ho, B. C., Andreasen, N. C., Nopolous, P., Arndt, S., Magnotta, V., & Flaum, M. (2003). Progressive structural brain abnormalities and their relation ship to clinical outcome: A longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry, 60(6), 585–594. doi:10.1001/archpsyc.60.6.585
23. van Ameslvoort, T., Daly, E., Henry, J., Rober son, D., Ng, V., Owen, M., Murphy, K. C., & Mur phy, D. G. M. (2004). Brain anatomy in adults with velocardiofacial syndrome with and without schizophrenia: Preliminary results of a structur al magnetic resonance imaging study. Archives of
General Psychiatry, 61(11), 1085–1096. doi:10.1001/ archpsyc.61.11.1085
24. Glausier, J. R., & Lewis, D. A. (2013). Dendritic spine pathology in schizophrenia. Neuroscience, 251, 90–107. doi:10.1016/j.neuroscience.2012.04.044
25. Xiong, L. (2022). Analysis on the treatment of gray matter heterotopia epilepsy. Advances in Social Science, Education and Humanities Research, 858–863. doi:10.2991/assehr.k.220110.162
26. Fry, A. E., Kerr, M. P., Gibbon, F., Turnpenny, P. D., Hamandi, K., Stoodley, N., Robertson, S. P., & Pilz, D. T. (2013). Neuropsychiatric disease in patients with periventricular heterotopia. The Journal of Neuropsychiatry and Clinical Neurosciences, 25(1), 26–31. doi:10.1176/appi.neuropsych.11110336
27. Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and treatment options. Physical Therapy, 39(9), 638–645. PMID: 25210417
NOW YOU SEE ME, NOW YOU DON’T: THE MYSTERIOUS PHENOMENON OF PHANTOM PREGNANCY
1. Medvei, V. C. (1987). The illness and death of Mary Tudor. Journal of the Royal Society of Medicine, 80(12), 766–770. doi: 10.1177/014107688708001214
2. Small, G. W. (1986). Pseudocyesis: An over view. Canadian Journal of Psychiatry. Revue Ca nadienne de Psychiatrie, 31(5), 452–457. doi: 10.1177/070674378603100514
3. Azizi, M., & Elyasi, F. (2017). Biopsychosocial view to pseudocyesis: A narrative review. International Journal of Reproductive Biomedicine, 15(9), 535–542. PMID: 29662961
4. Campos, S. J., Link D. (2016). Pseudocyesis. The Journal for Nurse Practitioners. 12, 390–394. doi: 10.1016/j.nurpra.2016.03.009
5. Dubravko, H. (2010). Pseudocyesis in peri- and postmenopausal women. Open Medicine, 5(3). doi: 10.2478/s11536-009-0084-8
6. Seeman, M. V. (2014). Pseudocyesis, delusional pregnancy, and psychosis: The birth of a delusion. World Journal of Clinical Cases, 2(8), 338. doi: 10.12998/wjcc.v2.i8.338
7. Ibekwe, P., & Achor, J. (2008). Psychosocial and cultural aspects of pseudocyesis. Indian Jour nal of Psychiatry, 50(2), 112. doi: 10.4103/00195545.42398
8. Tarín, J. J., Hermenegildo, C., García-Pérez, M. A., & Cano, A. (2013). Endocrinology and physiology of Pseudocyesis. Reproductive Biology and Endocri nology, 11(1), 39. doi: 10.1186/1477-7827-11-39
9. Rawindraraj, A. D., Basit, H., & Jialal, I. (2020).
58 GREY MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5 References
Physiology, anterior pituitary. StatPearls Publish ing. PMID: 29763073
10. Ozturk, S., & Demir, R. (2010). Particular functions of estrogen and progesterone in establishment of uterine receptivity and embryo implantation. His tology and Histopathology, 25(9), 1215–1228. doi: 10.14670/HH-25.1215
11. Pascual, Z. N., & Langaker, M. D. (2020). Physiology, pregnancy. StatPearls Publishing. PMID: 32644730
12. Grover, S., Sharma, A., Ghormode, D., & Rajpal, N. (2013). Pseudocyesis: A complication of anti psychotic-induced increased prolactin levels and weight gain. Journal of pharmacology & pharma cotherapeutics, 4(3), 214–216. doi: 10.4103/0976500X.114610
13. Freeman, M. E., Kanyicska, B., Lerant, A., & Nagy, G. (2000). Prolactin: Structure, function, and reg ulation of secretion. Physiological Reviews, 80(4), 1523–1631. doi: 10.1152/physrev.2000.80.4.1523
14. Bazer, F.W. (Ed.). (1998). Endocrinology of preg nancy. Humana Press Inc. doi: 10.1007/978-1-46121804-3
15. Bargiota, S. I., Bonotis, K. S., Messinis, I. E., & An gelopoulos, N. V. (2013). The effects of antipsy chotics on prolactin levels and women’s men struation. Schizophrenia Research and Treatment, 2013, 1–10. doi: 10.1155/2013/502697
16. Maguire, G. (2002). Prolactin elevation with anti psychotic medications: Mechanisms of action and clinical consequences. Journal of Clinical Psychi atry. PMID: 11913677
17. Majumdar, A., & Mangal, N. S. (2013). Hyperprolac tinemia. Journal of human reproductive sciences, 6(3), 168–175. doi: 10.4103/0974-1208.121400
18. Salleh, M. R. (2008). Life events, stress and ill ness. Malays J Med Sci, 10(4), 9-18. doi: 10.1016/j. nurpra.2016.03.009
19. Aguilera, G. (1998). Corticotropin releasing hor mone, receptor regulation and the stress re sponse. Trends in Endocrinology & Metabolism, 9(8), 329–336. doi: 10.1016/s1043-2760(98)000794
20. Froude, J. A. (1924). The reign of Mary Tudor. Dent.
21. Ouj, U. (2009). Pseudocyesis in a rural southeast Nigerian community. The journal of obstetrics and gynecology research, 35(4), 660–665. doi: 10.1111/j.1447-0756.2008.00997.x
22. Reblin, M., & Uchino, B. N. (2008). Social and emo tional support and its implication for health. Cur rent opinion in psychiatry, 21(2), 201–205. doi: 10.1097/YCO.0b013e3282f3ad89
TAKING NEW LEAPS INTO TREATMENT FOR PARKINSON’S DISEASE
1. DeMaagd, G., & Philip, A. (2015). Parkinson’s dis ease and its management. Pharmacy and Thera peutics, 40(8), 504–532. PMID: 26236139
2. Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H. (2014). The Neurobiological ba sis of cognitive impairment in Parkinson’s dis ease. Movement Disorders:Official Journal of the Movement Disorder Society, 29(5), 634–650. doi:10.1002/mds.25857
3. Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016). Pathophysiology of motor dysfunction in Parkinson’s disease as the rationale for drug treatment and rehabilitation. Parkinson’s Disease, 2016, Article 9832839. doi:10.1155/2016/9832839
4. Krishna, R., Ali, M., & Moustafa, A. A. (2014). Ef fects of combined MAO-B inhibitors and levodo pa vs. monotherapy in Parkinson’s disease. Fron tiers in Aging Neuroscience, 6, 180. doi:10.3389/ fnagi.2014.00180
5. Finberg, J. P., & Rabey, J. M. (2016). Inhibitors of MAO-A and MAO-B in psychiatry and neurolo gy. Frontiers in Pharmacology, 7. doi:10.3389/ fphar.2016.00340
6. Gordon, J. S. (1982). Holistic medicine: Advances and shortcomings. Western Journal of Medicine, 136(6), 546–551. PMID: 7113200
7. Bega, D., & Zadikoff, C. (2014). Complementary & alternative management of Parkinson’s disease: An evidence-based review of eastern influenced practices. Journal of Movement Disorders, 7(2), 57–66. doi:10.14802/jmd.14009
8. Marques, A., Marconcin, P., Werneck, A. O., Fer rari, G., Gouveia, É. R., Kliegel, M., Peralta, M., & Ihle, A. (2021). Bidirectional association between physical activity and dopamine across adulthood – A systematic review. Brain sciences, 11(7), 829. doi:10.3390/brainsci11070829
9. Lin, T. W., & Kuo, Y. M. (2013). Exercise benefits brain function: The monoamine connection. Brain Sciences, 3(1), 39–53. doi:10.3390/brainsci3010039
10. Jeong, Y. J., Hong, S. C., Lee, M. S., Park, M. C., Kim, Y. K., & Suh, C. M. (2005). Dance movement thera py improves emotional responses and modulates neurohormones in adolescents with mild depres sion. International Journal of Neuroscience, 115(12), 1711–1720. doi:10.1080/00207450590958574
11. Fontanesi, C., & DeSouza, J. F. X. (2021). Beauty that moves: Dance for Parkinson’s effects on affect, self-efficacy, gait symmetry, and dual task per
59 GREY
References
MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5
formance. Frontiers in Psychology, 11. doi:10.3389/ fpsyg.2020.600440
12. Westheimer, O., McRae, C., Henchcliffe, C., Fe sharaki, A., Glazman, S., Ene, H., & Bodis-Wollner, I. (2015). Dance for PD: A preliminary investiga tion of effects on motor function and quality of life among persons with Parkinson’s disease (PD). Journal of Neural Transmission, 122(9), 1263–1270. doi:10.1007/s00702-015-1380-x
13. Westheimer, O. (2008). Why dance for Parkinson’s disease. Topics in Geriatric Rehabilitation, 24(2), 127–140. doi:10.1097/01.tgr.0000318900.95313.af
14. Proske, U. (2006). Kinesthesia: The role of mus cle receptors. Muscle & Nerve, 34(5), 545–558. doi:10.1002/mus.20627
15. Dal Bello-Haas, V., Klassen, L., Sheppard, M. S., & Metcalfe, A. (2011). Psychometric properties of ac tivity, self-efficacy, and quality-of-life measures in individuals with Parkinson disease. Physiother apy Canada, 63(1), 47–57. doi: 10.3138/ptc.2009-08
16. Morgan, D. J., & Burholt, V. (2020). Loneliness as a biographical disruption—Theoretical implications for understanding changes in loneliness. The Journals of Gerontology: Series B, 75(9), 2029–2039. doi:10.1093/geronb/gbaa097
17. Houston, S., & McGill, A. (2013). A mixed-meth ods study into ballet for people living with Par kinson’s. Arts & Health, 5(2), 103–119. doi:10.1080/1 7533015.2012.745580
18. Houston, S. (2015). Feeling lovely: An examination of the value of beauty for people dancing with Parkinson’s. Dance Research Journal, 47(1), 27–43. doi:10.1017/S0149767715000042
19. Homann, K. (2010). Embodied concepts of neu robiology in dance/movement therapy practice. American Journal of Dance Therapy, 32, 80–99. doi:10.1007/s10465-010-9099-6
20. Šumec, R., Filip, P., Sheardová, K., & Bareš, M. (2015). Psychological benefits of nonpharmacolog ical methods aimed for improving balance in Par kinson’s disease: A systematic review. Behavioural Neurology, 2015, 1–16. doi:10.1155/2015/620674
21. Hulbert, S., Ashburn, A., Roberts, L., & Verheyden, G. (2017). Dance for Parkinson’s—The effects on whole body co-ordination during turning around. Complementary Therapies in Medicine, 32, 91–97. doi:10.1016/j.ctim.2017.03.012
22. Hall, M. F. E., & Church, F. C. (2020). Integrative medicine and health therapy for Parkinson dis ease. Topics in Geriatric Rehabilitation, 36(3), 176–186. doi:10.1097/tgr.0000000000000278
23. Gu, S., & Pei, J. (2017). Innovating Chinese herbal medicine: From traditional health practice to sci entific drug discovery. Frontiers in Pharmacology,
8. doi:10.3389/fphar.2017.00381
THE FUTURE OF TBI THERAPY STEMS FROM STEM CELLS
1. Shaikh, F., & Waseem, M. (2022). Head trauma. In StatPearls. StatPearls Publishing.
2. Markus H.S. (2004). Cerebral perfusion and stroke. Journal of Neurology, Neurosurgery & Psychiatry, 75, 353-361. doi:10.1136/jnnp.2003.025825.
3. Hasan, A., Deeb, G., Rahal, R., Atwi, K., Mondel lo, S., Marei, H. E., Gali, A., & Sleiman, E. (2017). Mesenchymal stem cells in the treatment of trau matic brain injury. Frontiers in Neurology, 8, 28. doi:10.3389/fneur.2017.00028.
4. Schmidt, E. A., Despas, F., Pavy-Le Traon, A., Czos nyka, Z., Pickard, J. D., Rahmouni, K., Pathak, A., & Senard, J. M. (2018). Intracranial pressure is a determinant of sympathetic activity. Frontiers in Physiology, 9, 11. doi:10.3389/fphys.2018.00011.
5. Galindo, L. T., Filippo, T. R., Semedo, P., Ariza, C. B., Moreira, C. M., Camara, N. O., & Porcionatto, M. A. (2011). Mesenchymal stem cell therapy modu lates the inflammatory response in experimental traumatic brain injury. Neurology Research Inter national, 2011, 564089. doi:10.1155/2011/564089.
6. Ankarcrona, M., Dypbukt, J. M., Bonfoco, E., Zhi votovsky, B., Orrenius, S., Lipton, S. A., & Nicotera, P. (1995). Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. Neuron, 15(4), 961–973. doi:10.1016/0896-6273(95)90186-8.
7. Chodobski, A., Zink, B. J., & Szmydynger-Cho dobska, J. (2011). Blood-brain barrier patho physiology in traumatic brain injury. Translational Stroke Research, 2(4), 492–516. doi:10.1007/ s12975-011-0125-x.
8. Volpi, P. C., Robba, C., Rota, M., Vargiolu, A., & Ci terio, G. (2018). Trajectories of early secondary insults correlate to outcomes of traumatic brain injury: results from a large, single centre, obser vational study. BMC Emergency Medicine, 18, 52. doi:10.1186/s12873-018-0197-y.
9. Galgano, M., Toshkezi, G., Qiu, X., Russell, T., Chin, L., & Zhao, L. R. (2017). Traumatic brain inju ry: Current treatment strategies and future en deavors. Cell Transplantation, 26(7), 1118–1130. doi:10.1177/0963689717714102.
10. Ludwig, P. E., Reddy, V., & Varacallo, M. (2022). Neuroanatomy, neurons. StatPearls Publishing.
11. Zhou, Y., Shao, A., Xu, W., Wu, H., & Deng, Y. (2019). Advance of stem cell treatment for traumatic brain injury. Frontiers in Cellular Neuroscience, 13, 301. doi:10.3389/fncel.2019.00301.
60 GREY
MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5 References
12. Schepici, G., Silvestro, S., Bramanti, P., & Mazzon, E. (2020). Traumatic brain injury and stem cells: An overview of clinical trials, the current treat ments and future therapeutic approaches. Me dicina (Kaunas, Lithuania), 56(3), 137. doi:10.3390/ medicina56030137.
13. Ullah, I., Subbarao, R. B., & Rho, G. J. (2015). Hu man mesenchymal stem cells - Current trends and future prospective. Bioscience Reports, 35(2), e00191. doi:10.1042/BSR20150025.
14. Ripa, R., George, T., & Sattar, Y. (2022). Physiology, Cardiac Muscle. StatPearls Publishing.
15. Zakrzewski, W., Dobrzyński, M., Szymonowicz, M., & Rybak, Z. (2019). Stem cells: Past, present, and future. Stem Cell Research & Therapy, 10(1), 68. doi:10.1186/s13287-019-1165-5.
16. Hernández, R., Jiménez-Luna, C., Perales-Adán, J., Perazzoli, G., Melguizo, C., & Prados, J. (2020). Differentiation of human mesenchymal stem cells towards neuronal lineage: Clinical trials in nervous system disorders. Biomolecules & Therapeutics, 28(1), 34–44. doi:10.4062/biomolther.2019.065.
17. Lykhmus, O., Koval, L., Voytenko, L., Uspenska, K., Komisarenko, S., Deryabina, O., Shuvalova, N., Kordium, V., Ustymenko, A., Kyryk, V., & Skok, M. (2019). Intravenously injected mesenchymal stem cells penetrate the brain and treat inflamma tion-induced brain damage and memory impair ment in mice. Frontiers in Pharmacology, 10, 355. doi:10.3389/fphar.2019.00355.
18. Karp, J. M., & Leng Teo, G. S. (2009). Mesenchy mal stem cell homing: The devil is in the de tails. Cell Stem Cell, 4(3), 206–216. doi:10.1016/j. stem.2009.02.001.
19. Menge, T., Zhao, Y., Zhao, J., Wataha, K., Gerber, M., Zhang, J., Letourneau, P., Redell, J., Shen, L., Wang, J., Peng, Z., Xue, H., Kozar, R., Cox, C. S., Jr, Khakoo, A. Y., Holcomb, J. B., Dash, P. K., & Pati, S. (2012). Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 re lease after traumatic brain injury. Science Trans lational Medicine, 4(161), 161ra150. doi:10.1126/sci translmed.3004660.
20. Dekmak, A., Mantash, S., Shaito, A., Toutonji, A., Ramadan, N., Ghazale, H., Kassem, N., Darwish, H., & Zibara, K. (2018). Stem cells and combina tion therapy for the treatment of traumatic brain injury. Behavioral Brain Research, 340, 49–62. doi:10.1016/j.bbr.2016.12.039.
TOXOPLASMA GONDII: THE BEAST LURKING IN THE LITTER BOX
1. Berdoy, M., Webster, J. P., & Macdonald, D. W. (2000). Fatal attraction in rats infected with Toxo plasma gondii. Proceedings of the Royal Society of London. Series B: Biological Sciences, 267(1452), 1591–1594. doi: 10.1098/rspb.2000.1182
2. Vyas, A., Kim, S. K., Giacomini, N., Boothroyd, J. C., & Sapolsky, R. M. (2007). Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proceed ings of the National Academy of Sciences, 104(15), 6442–6447. doi: 10.1073/pnas.0608310104
3. Olano, J. P., Weller, P. F., Guerrant, R. L., & Walk er, D. H. (2011). Principles of parasitism. Tropical Infectious Diseases: Principles, Pathogens and Practice, 1–7. doi: 10.1016/B978-0-7020-39355.00001-X
4. Daane, S. (2010). Leeches. Plastic Surgery Secrets Plus, 721–723. doi: 10.1016/B978-0-323-034708.00111-3
5. Dubey, J. P., Lindsay, D. S., & Speer, C. A. (1998). Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and de velopment of tissue cysts. Clinical Microbiology Reviews, 11(2), 267–299. doi: 10.1128/cmr.11.2.267
6. Attias, M., Teixeira, D. E., Benchimol, M., Vommaro, R. C., Crepaldi, P. H., & De Souza, W. (2020). The life-cycle of Toxoplasma gondii reviewed using animations. Parasites & Vectors, 13(1). doi: 10.1186/ s13071-020-04445-z
7. Calero-Bernal, R., & Gennari, S. M. (2019). Clini cal toxoplasmosis in dogs and cats: An update. Frontiers in Veterinary Science, 6. doi: 10.3389/ fvets.2019.00054
8. Flegr, J., Prandota, J., Sovičková, M., & Israili, Z. H. (2014). Toxoplasmosis – a global threat. correla tion of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE, 9(3). doi: 10.1371/journal.pone.0090203
9. Jones, J. L., & Dubey, J. P. (2012). Foodborne toxo plasmosis. Clinical Infectious Diseases, 55(6), 845–851. doi: 10.1093/cid/cis508
10. Daneman, R., & Prat, A. (2015). The blood–brain barrier. Cold Spring Harbor Perspectives in Biolo gy, 7(1). doi: 10.1101/cshperspect.a020412
11. An, R., Tang, Y., Chen, L., Cai, H., Lai, D. H., Liu, K., Wan, L., Gong, L., Yu, L., Luo, Q., Shen, J., Lun, Z. R., Ayala, F. J., & Du, J. (2018). Encephalitis is me diated by rop18 of Toxoplasma gondii , a severe pathogen in AIDS patients. Proceedings of the Na tional Academy of Sciences, 115(23). doi: 10.1073/
61 GREY MATTERS
AT VASSAR COLLEGE | ISSUE 5 References
JOURNAL
pnas.1801118115
12. Wohlfert, E. A., Blader, I. J., & Wilson, E. H. (2017). Brains and brawn: Toxoplasma infections of the central nervous system and skeletal mus cle. Trends in Parasitology, 33(7), 519–531. doi: 10.1016/j.pt.2017.04.001
13. Suzuki, Y., Sa, Q., Ochiai, E., Mullins, J., Yolken, R., & Halonen, S. K. (2014). Cerebral toxoplasmosis. Toxoplasma Gondii, 755–796. doi: 10.1016/b978-012-396481-6.00023-4
14. Mendez, O. A., Flores Machado, E., Lu, J., & Koshy, A. A. (2021). Injection with Toxoplasma gondii pro tein affects neuron health and survival. ELife, 10. doi: 10.7554/elife.67681
15. Rai, K. R., Shrestha, P., Yang, B., Chen, Y., Liu, S., Maarouf, M., & Chen, J. L. (2021). Acute infection of viral pathogens and their innate immune es cape. Frontiers in Microbiology, 12. doi: 10.3389/ fmicb.2021.672026
16. Pal, M. M. (2021). Glutamate: The master neu rotransmitter and its implications in chronic stress and mood disorders. Frontiers in Human Neuroscience, 15. doi: 10.3389/fnhum.2021.722323
17. Zhou, Y., & Danbolt, N. C. (2014). Glutamate as a neurotransmitter in the healthy brain. Journal of Neural Transmission, 121(8), 799–817. doi: 10.1007/ s00702-014-1180-8
18. Armada-Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves-Ribeiro, J., Rei, N., Pin to, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., Se bastião, A. M., Crunelli, V., & Vaz, S. H. (2020). Go ing the extra (synaptic) mile: Excitotoxicity as the road toward neurodegenerative diseases. Fron tiers in Cellular Neuroscience, 14. doi: 10.3389/ fncel.2020.00090
19. Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R., & Sharma, P. L. (2013). Excitotoxicity: Bridge to various triggers in neurodegenerative disor ders. European Journal of Pharmacology, 698(13), 6–18. doi: 10.1016/j.ejphar.2012.10.032
20. Henao-Martínez, A. F., Franco-Paredes, C., Pales tine, A. G., & Montoya, J. G. (2018). Symptomatic acute toxoplasmosis in returning travelers. Open Forum Infectious Diseases, 5(4). doi: 10.1093/ofid/ ofy058
21. Havlíček, J., Gašová, Z., Smith, A. P., Zvára, K., & Flegr, J. (2001). Decrease of psychomotor per formance in subjects with latent ‘asymptomatic’ toxoplasmosis. Parasitology, 122(5), 515–520. doi: 10.1017/s0031182001007624
22. Flegr, J., Zitková, Š., Kodym, P., & Frynta, D. (1996). Induction of changes in human behaviour by the parasitic protozoan Toxoplasma gondii. Parasitol ogy, 113(1), 49–54. doi: 10.1017/s0031182000066269
23. Flegr, J., Kodym, P., & Tolarová, V. (2000). Correla tion of duration of latent Toxoplasma gondii in fection with personality changes in women. Bi ological Psychology, 53(1), 57–68. doi: 10.1016/ s0301-0511(00)00034-x
24. Morais, F. B., Arantes, T. E., & Muccioli, C. (2017). Seroprevalence and manifestations of ocular toxoplasmosis in patients with schizophrenia. Oc ular Immunology and Inflammation, 27(1), 134–137. doi: 10.1080/09273948.2017.1408843
25. Fuglewicz, A., Piotrowski, P., & Stodolak, A. (2017). Relationship between toxoplasmosis and schizo phrenia: A Review. Advances in Clinical and Exper imental Medicine, 26(6), 1033–1038. doi: 10.17219/ acem/61435
26. Zhang, X., Ge, T. tong, Yin, G., Cui, R., Zhao, G., & Yang, W. (2018). Stress-induced functional alter ations in amygdala: Implications for neuropsychi atric diseases. Frontiers in Neuroscience, 12. doi: 10.3389/fnins.2018.00367
27. Flegr, J., Havlícek, J., Kodym, P., Malý, M., & Smahel, Z. (2002). Increased risk of traffic accidents in subjects with latent toxoplasmosis: A retrospec tive case-control study. BMC Infectious Diseases, 2(1). doi: 10.1186/1471-2334-2-11
28. Dupont, C. D., Christian, D. A., & Hunter, C. A. (2012). Immune response and immunopathology during toxoplasmosis. Seminars in Immunopa thology, 34(6), 793–813. doi: 10.1007/s00281-0120339-3
29. Allen, B. M., Hiam, K. J., Burnett, C. E., Venida, A., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020). Systemic dys function and plasticity of the immune macroen vironment in cancer models. Nature Medicine, 26(7), 1125–1134. doi: 10.1038/s41591-020-0892-6
30. Pathogenesis and natural history of HIV infection. (2001). Outpatient Management of HIV Infection, 33–48. doi: 10.1201/b14254-4
31. Harpaz, R., Dahl, R. M., & Dooling, K. L. (2016). Prevalence of immunosuppression among US adults, 2013. JAMA, 316(23), 2547. doi: 10.1001/ jama.2016.16477
32. Lee, S.-B., & Lee, T.-G. (2017). Toxoplasmic enceph alitis in patient with acquired immunodeficiency syndrome. Brain Tumor Research and Treatment, 5(1), 34. doi: 10.14791/btrt.2017.5.1.34
33. Del Grande, C., Galli, L., Schiavi, E., Dell’Osso, L., & Bruschi, F. (2017). Is Toxoplasma gondii a trigger of bipolar disorder? Pathogens, 6(1), 3. doi: 10.3390/ pathogens6010003
34. Robert-Gangneux, F., & Dardé, M.-L. (2012). Epi demiology of and diagnostic strategies for toxo plasmosis. Clinical Microbiology Reviews, 25(2),
62 GREY MATTERS JOURNAL AT VASSAR COLLEGE | ISSUE 5 References
264–296. doi: 10.1128/cmr.05013-11
35. Torrey, E. F., & Yolken, R. H. (2003). Toxoplas ma gondii and schizophrenia. Emerging Infec tious Diseases, 9(11), 1375-1380. doi: 10.3201/ eid0911.030143
36. Robbins, J. R., Zeldovich, V. B., Poukchanski, A., Boothroyd, J. C., & Bakardjiev, A. I. (2012). Tissue barriers of the human placenta to infection with Toxoplasma gondii. Infection and Immunity, 80(1), 418–428. doi: 10.1128/iai.05899-11
37. Bollani, L., Auriti, C., Achille, C., Garofoli, F., De Rose, D. U., Meroni, V., Salvatori, G., & Tzialla, C. (2022). Congenital toxoplasmosis: The state of the art. Frontiers in Pediatrics, 10. doi: 10.3389/ fped.2022.894573
38. McAuley, J. B. (2014). Congenital toxoplasmosis. Journal of the Pediatric Infectious Diseases Soci ety, 3(suppl_1). doi: 10.1093/jpids/piu077
39. Rajapakse, S., Weeratunga, P., Rodrigo, C., de Silva, N. L., & Fernando, S. D. (2017). Prophylax is of human toxoplasmosis: A systematic review. Pathogens and Global Health, 111(7), 333–342. doi: 10.1080/20477724.2017.1370528
40. Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., & Montoya, J. G. (2018). Treatment of toxoplas mosis: Historical perspective, animal models, and current clinical practice. Clinical Microbiology Re views, 31(4). doi: 10.1128/cmr.00057-17
41. Derouin, F., & Pelloux, H. (2008). Prevention of toxoplasmosis in transplant patients. Clinical Mi crobiology and Infection, 14(12), 1089–1101. doi: 10.1111/j.1469-0691.2008.02091.x
42. Lai, B. S., Witola, W. H., El Bissati, K., Zhou, Y., Mui, E., Fomovska, A., & McLeod, R. (2012). Molecular target validation, antimicrobial delivery, and po tential treatment of Toxoplasma gondii infections. Proceedings of the National Academy of Sciences, 109(35), 14182–14187. doi: 10.1073/pnas.1208775109
43. Montazeri, M., Mehrzadi, S., Sharif, M., Sarvi, S., Tanzifi, A., Aghayan, S. A., & Daryani, A. (2018). Drug resistance in Toxoplasma gondii. Frontiers in Microbiology, 9. doi: 10.3389/fmicb.2018.02587
44. Jones-Brando, L. (2003). Drugs used in the treatment of schizophrenia and bipolar disor der inhibit the replication of Toxoplasma gondii. Schizophrenia Research, 62(3), doi:10.1016/s09209964(02)00357-2
45. Wang, Z.-D., Liu, H.-H., Ma, Z.-X., Ma, H.-Y., Li, Z.Y., Yang, Z.-B., Zhu, X.-Q., Xu, B., Wei, F., & Liu, Q. (2017). Toxoplasma gondii infection in immuno compromised patients: A systematic review and meta-analysis. Frontiers in Microbiology, 8. doi: 10.3389/fmicb.2017.00389
GREY MATTERS JOURNAL AT VASSAR COLLEGE |
ISSUE 5
63
References